KDR and gastric cancer: VEGFR2 has been widely targeted for the anti-angiogenic treatment of tumors, as well as diagnosis of various cancers, such as breast and gastric cancers (Masuda et al., 2012; Lian et al., 2019; Masłowska et al., 2021).